CL2015002756A1 - Moléculas fc biespecíficas - Google Patents
Moléculas fc biespecíficasInfo
- Publication number
- CL2015002756A1 CL2015002756A1 CL2015002756A CL2015002756A CL2015002756A1 CL 2015002756 A1 CL2015002756 A1 CL 2015002756A1 CL 2015002756 A CL2015002756 A CL 2015002756A CL 2015002756 A CL2015002756 A CL 2015002756A CL 2015002756 A1 CL2015002756 A1 CL 2015002756A1
- Authority
- CL
- Chile
- Prior art keywords
- bispecific
- molecules
- cell
- bind
- antibody
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/71—Decreased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Abstract
Fc BIESPECÍFICA (Bi-Fc) QUE PUEDE LIGAR DOS PROTEÍNAS DIFERENTES Y CONTIENE UNA REGIÓN Fc DE UN ANTICUERPO, LA CUAL ESPECIFICAMENTE LIGA UNA CÉLULA OBJETIVO Y UNA CÉLULA EFECTORA INMUNITARIA.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361791424P | 2013-03-15 | 2013-03-15 |
Publications (1)
Publication Number | Publication Date |
---|---|
CL2015002756A1 true CL2015002756A1 (es) | 2016-04-15 |
Family
ID=50489434
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CL2015002756A CL2015002756A1 (es) | 2013-03-15 | 2015-09-15 | Moléculas fc biespecíficas |
Country Status (21)
Country | Link |
---|---|
US (5) | US20140302037A1 (es) |
EP (1) | EP2970477B1 (es) |
JP (2) | JP6535654B2 (es) |
KR (1) | KR20150139531A (es) |
CN (1) | CN105229031A (es) |
AP (1) | AP2015008773A0 (es) |
AU (1) | AU2014228829B2 (es) |
BR (1) | BR112015023431A2 (es) |
CA (1) | CA2902961C (es) |
CL (1) | CL2015002756A1 (es) |
CR (1) | CR20150573A (es) |
EA (1) | EA201591814A1 (es) |
HK (1) | HK1214275A1 (es) |
IL (1) | IL241354A0 (es) |
MA (1) | MA38400A1 (es) |
MX (2) | MX2015012187A (es) |
PE (1) | PE20151998A1 (es) |
PH (1) | PH12015502083A1 (es) |
SG (1) | SG11201506647SA (es) |
TN (1) | TN2015000379A1 (es) |
WO (1) | WO2014144722A2 (es) |
Families Citing this family (144)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2794650B1 (en) * | 2011-12-21 | 2019-08-14 | Amgen Inc. | Variant fc-polypeptides with enhanced binding to the neonatal fc receptor |
US20140154253A1 (en) * | 2012-07-13 | 2014-06-05 | Zymeworks Inc. | Bispecific Asymmetric Heterodimers Comprising Anti-CD3 Constructs |
AU2014236769B2 (en) * | 2013-03-15 | 2018-09-27 | Amgen Inc. | Heterodimeric bispecific antibodies |
US20140302037A1 (en) * | 2013-03-15 | 2014-10-09 | Amgen Inc. | BISPECIFIC-Fc MOLECULES |
HUE048312T2 (hu) | 2013-05-03 | 2020-07-28 | Ohio State Innovation Foundation | CS-1 specifikus kiméra antigén receptor módosított immuneffektor sejtek |
JP6817064B2 (ja) | 2013-11-27 | 2021-01-20 | ザイムワークス,インコーポレイテッド | Her2を標的とする二重特異性抗原結合性コンストラクト |
PL3192812T3 (pl) | 2013-12-17 | 2020-10-19 | Genentech, Inc. | Przeciwciała anty-CD3 i sposoby ich zastosowania |
TWI726842B (zh) | 2014-04-07 | 2021-05-11 | 日商中外製藥股份有限公司 | 免疫活化抗原結合分子 |
MX2016014434A (es) * | 2014-05-13 | 2017-02-23 | Chugai Pharmaceutical Co Ltd | Molecula de union a antigeno redirigida a celulas t para celulas que tienen funcion de inmunosupresion. |
GB201411320D0 (en) | 2014-06-25 | 2014-08-06 | Ucb Biopharma Sprl | Antibody construct |
BR112017001579A2 (pt) | 2014-07-25 | 2017-11-21 | Cytomx Therapeutics Inc | anticorpos anti-cd3, anticorpos anti-cd3 ativáveis, anticorpos anti-cd3 multiespecíficos, anticorpos anti-cd3 ativáveis multiespecíficos e métodos de uso dos mesmos |
TW201609812A (zh) | 2014-07-31 | 2016-03-16 | 安美基研究(慕尼黑)公司 | 最佳化之跨物種特異性雙特異性單鏈抗體構築體 |
AU2015323313B2 (en) * | 2014-09-25 | 2021-04-01 | Amgen Inc. | Protease-activatable bispecific proteins |
US11566082B2 (en) | 2014-11-17 | 2023-01-31 | Cytiva Bioprocess R&D Ab | Mutated immunoglobulin-binding polypeptides |
RS61134B1 (sr) | 2014-11-20 | 2020-12-31 | Hoffmann La Roche | Kombinovana terapija bispecifičnim antigen vezujućim molekulima koji aktiviraju t ćelije za cd3 i folatni receptor 1 (folr1), i antagonistima vezivanja ose pd-1 |
AU2016219785B2 (en) * | 2015-02-20 | 2021-10-28 | Ohio State Innovation Foundation | Bivalent antibody directed against NKG2D and tumor associated antigens |
CN108367057B (zh) | 2015-04-06 | 2022-11-22 | 赛通免疫股份有限公司 | 用于胶质母细胞瘤的egfr导向的car疗法 |
MX2017013348A (es) | 2015-04-17 | 2018-08-01 | Amgen Res Munich Gmbh | Construcciones de anticuerpos biespecificos contra cdh3 y cd3. |
JP2018520642A (ja) * | 2015-05-01 | 2018-08-02 | ジェネンテック, インコーポレイテッド | マスク抗cd3抗体及びその使用方法 |
WO2016182064A1 (ja) * | 2015-05-13 | 2016-11-17 | 中外製薬株式会社 | 多重抗原結合分子融合体、医薬組成物、線状エピトープの同定方法、および多重抗原結合分子融合体の製造方法 |
ES2889906T3 (es) | 2015-05-21 | 2022-01-14 | Harpoon Therapeutics Inc | Proteínas de unión triespecíficas y usos médicos |
WO2017011413A1 (en) * | 2015-07-10 | 2017-01-19 | Duke University | Bispecific molecules comprising an hiv-1 envelope targeting arm |
WO2017011414A1 (en) * | 2015-07-10 | 2017-01-19 | Duke University | Bispecific molecules comprising an hiv-1 envelope targeting arm |
TWI717375B (zh) | 2015-07-31 | 2021-02-01 | 德商安美基研究(慕尼黑)公司 | Cd70及cd3抗體構築體 |
TWI796283B (zh) | 2015-07-31 | 2023-03-21 | 德商安美基研究(慕尼黑)公司 | Msln及cd3抗體構築體 |
TWI829617B (zh) | 2015-07-31 | 2024-01-21 | 德商安美基研究(慕尼黑)公司 | Flt3及cd3抗體構築體 |
TW202346349A (zh) | 2015-07-31 | 2023-12-01 | 德商安美基研究(慕尼黑)公司 | Dll3及cd3抗體構築體 |
TWI744242B (zh) | 2015-07-31 | 2021-11-01 | 德商安美基研究(慕尼黑)公司 | Egfrviii及cd3抗體構築體 |
JO3620B1 (ar) | 2015-08-05 | 2020-08-27 | Amgen Res Munich Gmbh | مثبطات نقطة فحص مناعية للاستخدام في علاج سرطانات محمولة عبر الدم |
CN107921130A (zh) * | 2015-08-17 | 2018-04-17 | 宏观基因有限公司 | 能够结合b7‑h3和cd3的双特异性单价双抗体及其用途 |
AR106199A1 (es) * | 2015-10-02 | 2017-12-20 | Hoffmann La Roche | Moléculas de unión a antígeno biespecíficas activadoras de células t |
JP7044700B2 (ja) * | 2015-10-02 | 2022-03-30 | エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト | 二重特異性抗ceaxcd3 t細胞活性化抗原結合分子 |
IL301140A (en) | 2015-10-25 | 2023-05-01 | The Usa As Represented By The Sec Dep Of Health And Human Services | Trispecific and/or terrivalent binding proteins for the prevention or treatment of HIV infection |
WO2017070943A1 (zh) * | 2015-10-30 | 2017-05-04 | 江苏众红生物工程创药研究院有限公司 | 双特异性抗体、其制备方法和用途 |
JP6925278B2 (ja) | 2015-11-18 | 2021-08-25 | 中外製薬株式会社 | 液性免疫応答の増強方法 |
JP6931329B2 (ja) | 2015-11-18 | 2021-09-01 | 中外製薬株式会社 | 免疫抑制機能を有する細胞に対するt細胞リダイレクト抗原結合分子を用いた併用療法 |
CN115920030A (zh) | 2015-12-09 | 2023-04-07 | 豪夫迈·罗氏有限公司 | Ii型抗cd20抗体用于降低抗药物抗体形成 |
CA3006529A1 (en) | 2016-01-08 | 2017-07-13 | F. Hoffmann-La Roche Ag | Methods of treating cea-positive cancers using pd-1 axis binding antagonists and anti-cea/anti-cd3 bispecific antibodies |
MA43955B1 (fr) | 2016-02-03 | 2022-02-28 | Amgen Inc | Anticorps anti-bcma et anti-cd3 bispécifiques de format bite |
CN114716557A (zh) | 2016-02-03 | 2022-07-08 | 安进研发(慕尼黑)股份有限公司 | Psma和cd3双特异性t细胞接合抗体构建体 |
EA039859B1 (ru) * | 2016-02-03 | 2022-03-21 | Эмджен Рисерч (Мюник) Гмбх | Биспецифические конструкты антител, связывающие egfrviii и cd3 |
JP7082604B2 (ja) | 2016-03-21 | 2022-06-08 | マレンゴ・セラピューティクス,インコーポレーテッド | 多重特異性および多機能性分子ならびにその使用 |
PL3433280T3 (pl) | 2016-03-22 | 2023-07-31 | F. Hoffmann-La Roche Ag | Dwuswoiste cząsteczki limfocytów T aktywowane przez proteazy |
CR20180453A (es) * | 2016-03-22 | 2018-12-05 | Hoffmann La Roche | Moleculas biespecíficas de células t activadas por proteasas |
RS64771B1 (sr) | 2016-04-13 | 2023-11-30 | Sanofi Sa | Trispecifični i/ili trovalentni vezujući proteini |
JOP20170091B1 (ar) | 2016-04-19 | 2021-08-17 | Amgen Res Munich Gmbh | إعطاء تركيبة ثنائية النوعية ترتبط بـ cd33 وcd3 للاستخدام في طريقة لعلاج اللوكيميا النخاعية |
ES2874974T3 (es) | 2016-05-11 | 2021-11-05 | Cytiva Bioprocess R & D Ab | Matriz de separación |
US10889615B2 (en) | 2016-05-11 | 2021-01-12 | Cytiva Bioprocess R&D Ab | Mutated immunoglobulin-binding polypeptides |
JP7106187B2 (ja) | 2016-05-11 | 2022-07-26 | サイティバ・バイオプロセス・アールアンドディ・アクチボラグ | 分離マトリックスを保存する方法 |
US10730908B2 (en) | 2016-05-11 | 2020-08-04 | Ge Healthcare Bioprocess R&D Ab | Separation method |
US10654887B2 (en) | 2016-05-11 | 2020-05-19 | Ge Healthcare Bio-Process R&D Ab | Separation matrix |
CN109311948B (zh) | 2016-05-11 | 2022-09-16 | 思拓凡生物工艺研发有限公司 | 清洁和/或消毒分离基质的方法 |
US10703774B2 (en) | 2016-09-30 | 2020-07-07 | Ge Healthcare Bioprocess R&D Ab | Separation method |
WO2017201488A1 (en) | 2016-05-20 | 2017-11-23 | Harpoon Therapeutics, Inc. | Single domain serum albumin binding protein |
US11623958B2 (en) | 2016-05-20 | 2023-04-11 | Harpoon Therapeutics, Inc. | Single chain variable fragment CD3 binding proteins |
KR102365977B1 (ko) | 2016-05-20 | 2022-02-22 | 하푼 테라퓨틱스, 인크. | 단일 쇄 가변 단편 cd3 결합 단백질 |
CA3030841A1 (en) | 2016-07-14 | 2018-01-18 | Fred Hutchinson Cancer Research Center | Multiple bi-specific binding domain constructs with different epitope binding to treat cancer |
IL285146B (en) | 2016-07-22 | 2022-09-01 | Amgen Inc | Methods for purifying proteins involving fc |
JP2020503260A (ja) | 2016-11-15 | 2020-01-30 | ジェネンテック, インコーポレイテッド | 抗cd20/抗cd3二重特異性抗体による処置のための投与 |
BR112019010602A2 (pt) | 2016-11-23 | 2019-12-17 | Harpoon Therapeutics Inc | proteínas trispecíficas para psma e métodos de uso |
CA3044659A1 (en) | 2016-11-23 | 2018-05-31 | Harpoon Therapeutics, Inc. | Prostate specific membrane antigen binding protein |
JOP20190189A1 (ar) | 2017-02-02 | 2019-08-01 | Amgen Res Munich Gmbh | تركيبة صيدلانية ذات درجة حموضة منخفضة تتضمن بنيات جسم مضاد يستهدف الخلية t |
US20200291089A1 (en) | 2017-02-16 | 2020-09-17 | Elstar Therapeutics, Inc. | Multifunctional molecules comprising a trimeric ligand and uses thereof |
EP3589662A4 (en) | 2017-02-28 | 2020-12-30 | Harpoon Therapeutics, Inc. | INDUCTIBLE MONOVALENT ANTIGBINDING PROTEIN |
EA201892312A1 (ru) | 2017-03-17 | 2019-04-30 | Санофи | Триспецифические и/или тривалентные связывающие белки |
CA3060856A1 (en) | 2017-05-05 | 2018-11-08 | Amgen Inc. | Pharmaceutical composition comprising bispecific antibody constructs for improved storage and administration |
JP7090347B2 (ja) | 2017-05-12 | 2022-06-24 | ハープーン セラピューティクス,インク. | メソテリン結合タンパク質 |
CA3063362A1 (en) | 2017-05-12 | 2018-11-15 | Harpoon Therapeutics, Inc. | Msln targeting trispecific proteins and methods of use |
EP3630836A1 (en) | 2017-05-31 | 2020-04-08 | Elstar Therapeutics, Inc. | Multispecific molecules that bind to myeloproliferative leukemia (mpl) protein and uses thereof |
WO2019035938A1 (en) | 2017-08-16 | 2019-02-21 | Elstar Therapeutics, Inc. | MULTISPECIFIC MOLECULES BINDING TO BCMA AND USES THEREOF |
CR20200195A (es) | 2017-10-13 | 2020-08-14 | Harpoon Therapeutics Inc | Proteínas de unión a antigenos de maduraciòn de celulas b |
BR112020007196A2 (pt) | 2017-10-13 | 2020-12-01 | Harpoon Therapeutics, Inc. | proteínas triespecíficas e métodos de uso |
US11472889B2 (en) | 2017-10-14 | 2022-10-18 | Cytomx Therapeutics, Inc. | Antibodies, activatable antibodies, bispecific antibodies, and bispecific activatable antibodies and methods of use thereof |
BR112020011627A2 (pt) | 2017-12-11 | 2020-11-17 | Amgen Inc. | processo de fabricação contínuo para produtos de anticorpos biespecíficos |
UY38041A (es) | 2017-12-29 | 2019-06-28 | Amgen Inc | Construcción de anticuerpo biespecífico dirigida a muc17 y cd3 |
JP7475275B2 (ja) | 2018-02-08 | 2024-04-26 | ジェネンテック, インコーポレイテッド | 二重特異性抗原結合分子及びその使用方法 |
CA3091683A1 (en) | 2018-03-13 | 2019-09-19 | Phanes Therapeutics, Inc. | Anti-folate receptor 1 antibodies and uses thereof |
WO2019178362A1 (en) | 2018-03-14 | 2019-09-19 | Elstar Therapeutics, Inc. | Multifunctional molecules that bind to calreticulin and uses thereof |
WO2019178364A2 (en) | 2018-03-14 | 2019-09-19 | Elstar Therapeutics, Inc. | Multifunctional molecules and uses thereof |
CN111867612A (zh) | 2018-03-26 | 2020-10-30 | 阿尔托生物科学有限责任公司 | 抗PDL1、IL-15和TGF-β受体组合分子 |
EP3818083A2 (en) | 2018-07-03 | 2021-05-12 | Elstar Therapeutics, Inc. | Anti-tcr antibody molecules and uses thereof |
TW202021616A (zh) | 2018-07-30 | 2020-06-16 | 美商安進公司 | 結合至cd33和cd3的雙特異性抗體構建體之延長投與 |
TW202019477A (zh) | 2018-07-31 | 2020-06-01 | 德商安美基研究(慕尼黑)公司 | BCMAxCD3抗體構建體之給藥方案 |
MX2021001353A (es) | 2018-08-03 | 2021-04-13 | Amgen Res Munich Gmbh | Constructos de anticuerpos para cldn18.2 y cd3. |
US10815311B2 (en) | 2018-09-25 | 2020-10-27 | Harpoon Therapeutics, Inc. | DLL3 binding proteins and methods of use |
MX2021003543A (es) | 2018-09-27 | 2021-06-23 | Xilio Dev Inc | Polipeptidos de citocinas enmascaradas. |
EP3856781A1 (en) | 2018-09-28 | 2021-08-04 | Amgen Inc. | Antibodies against soluble bcma |
US20210395298A1 (en) | 2018-10-11 | 2021-12-23 | Amgen Inc. | Downstream processing of bispecific antibody constructs |
CA3115296A1 (en) | 2018-10-23 | 2020-04-30 | Amgen Inc. | Automatic calibration and automatic maintenance of raman spectroscopic models for real-time predictions |
PE20211279A1 (es) * | 2018-10-23 | 2021-07-19 | Dragonfly Therapeutics Inc | Proteinas heterodimericas fusionadas con fc |
BR112021012338A2 (pt) | 2018-12-24 | 2021-09-14 | Sanofi | Proteínas de ligação multiespecíficas com domínios fab mutantes |
TW202043253A (zh) | 2019-01-28 | 2020-12-01 | 美商安進公司 | 藉由將藥物物質和藥物產品過程整體化的生物製劑製造之連續製造過程 |
GB2599227B (en) | 2019-02-21 | 2024-05-01 | Marengo Therapeutics Inc | Multifunctional molecules that bind to T cells and uses thereof to treat autoimmune disorders |
WO2020172596A1 (en) | 2019-02-21 | 2020-08-27 | Elstar Therapeutics, Inc. | Anti-tcr antibody molecules and thereof |
GB2599229B (en) | 2019-02-21 | 2024-04-24 | Marengo Therapeutics Inc | Multifunctional molecules that bind to calreticulin and uses thereof |
GB2597851A (en) | 2019-02-21 | 2022-02-09 | Marengo Therapeutics Inc | Antibody molecules that bind to NKP30 and uses thereof |
WO2020172571A1 (en) | 2019-02-21 | 2020-08-27 | Elstar Therapeutics, Inc. | Multifunctional molecules that bind to t cell related cancer cells and uses thereof |
US11613576B2 (en) | 2019-04-09 | 2023-03-28 | Sanofi | Trispecific binding proteins, methods, and uses thereof |
MX2021014644A (es) | 2019-06-13 | 2022-04-06 | Amgen Inc | Control de perfusion basado en biomasa automatizado en la fabricacion de productos biologicos. |
WO2021050640A1 (en) | 2019-09-10 | 2021-03-18 | Amgen Inc. | Purification method for bispecific antigen-binding polypeptides with enhanced protein l capture dynamic binding capacity |
EP4054590A1 (en) | 2019-11-04 | 2022-09-14 | Amgen Inc. | Methods for treating leukemia |
EP3819007A1 (en) | 2019-11-11 | 2021-05-12 | Amgen Research (Munich) GmbH | Dosing regimen for anti-bcma agents |
US20220396599A1 (en) | 2019-11-13 | 2022-12-15 | Amgen Inc. | Method for Reduced Aggregate Formation in Downstream Processing of Bispecific Antigen-Binding Molecules |
CA3163950A1 (en) | 2019-12-13 | 2021-06-17 | Genentech, Inc. | Anti-ly6g6d antibodies and methods of use |
CA3164129A1 (en) | 2019-12-20 | 2021-06-24 | Amgen Inc. | Mesothelin-targeted cd40 agonistic multispecific antibody constructs for the treatment of solid tumors |
WO2021138407A2 (en) | 2020-01-03 | 2021-07-08 | Marengo Therapeutics, Inc. | Multifunctional molecules that bind to cd33 and uses thereof |
US20230093169A1 (en) | 2020-01-22 | 2023-03-23 | Amgen Research (Munch) Gmbh | Combinations of antibody constructs and inhibitors of cytokine release syndrome and uses thereof |
WO2021158469A1 (en) | 2020-02-03 | 2021-08-12 | Amgen Inc. | Multivariate bracketing approach for sterile filter validation |
CN115768463A (zh) | 2020-02-21 | 2023-03-07 | 哈普恩治疗公司 | Flt3结合蛋白及使用方法 |
WO2021183861A1 (en) | 2020-03-12 | 2021-09-16 | Amgen Inc. | Method for treatment and prophylaxis of crs in patients comprising a combination of bispecifc antibodies binding to cds x cancer cell and tnfalpha or il-6 inhibitor |
WO2021188851A1 (en) | 2020-03-19 | 2021-09-23 | Amgen Inc. | Antibodies against mucin 17 and uses thereof |
EP4139363A1 (en) | 2020-04-24 | 2023-03-01 | Marengo Therapeutics, Inc. | Multifunctional molecules that bind to t cell related cancer cells and uses thereof |
EP4153633A1 (en) | 2020-05-19 | 2023-03-29 | Amgen Inc. | Mageb2 binding constructs |
MX2022014902A (es) | 2020-05-29 | 2023-01-04 | Amgen Inc | Administracion mitigadora de efectos adversos de un constructo biespecifico que se une a cd33 y cd3. |
CN116761818A (zh) | 2020-08-26 | 2023-09-15 | 马伦戈治疗公司 | 检测trbc1或trbc2的方法 |
WO2022046920A2 (en) | 2020-08-26 | 2022-03-03 | Marengo Therapeutics, Inc. | Multifunctional molecules that bind to calreticulin and uses thereof |
GB2616128A (en) | 2020-08-26 | 2023-08-30 | Marengo Therapeutics Inc | Antibody molecules that bind to NKp30 and uses thereof |
WO2022060878A1 (en) | 2020-09-16 | 2022-03-24 | Amgen Inc. | Methods for treating prostate cancer |
AU2021345124A1 (en) | 2020-09-16 | 2023-03-30 | Amgen Inc. | Methods for administering therapeutic doses of bispecific T-cell engaging molecules for the treatment of cancer |
BR112023008629A2 (pt) | 2020-11-06 | 2023-10-03 | Amgen Inc | Construtos de polipeptídeos que se ligam seletivamente a cldn6 e cd3 |
CN116323671A (zh) | 2020-11-06 | 2023-06-23 | 安进公司 | 具有增加的选择性的多靶向性双特异性抗原结合分子 |
TW202233678A (zh) | 2020-11-06 | 2022-09-01 | 德商安美基研究(慕尼黑)公司 | 具有增強的剪切特徵的多肽 |
BR112023008670A2 (pt) | 2020-11-06 | 2024-02-06 | Amgen Inc | Construtos polipeptídicos ligados à cd3 |
TW202233682A (zh) | 2020-11-10 | 2022-09-01 | 美商安進公司 | 用於投與BCMAxCD3結合分子之方法 |
TW202233684A (zh) * | 2020-11-18 | 2022-09-01 | 美商泰尼歐生物公司 | 結合於葉酸受體α之重鏈抗體 |
US11883432B2 (en) | 2020-12-18 | 2024-01-30 | Century Therapeutics, Inc. | Chimeric antigen receptor system with adaptable receptor specificity |
HUP2100038A1 (hu) * | 2021-02-03 | 2022-08-28 | Richter Gedeon Nyrt | Mutáltatott rekombináns ACE2-Fc fúziós fehérjék COVID-19 fertõzések kezelésére |
JP2024509877A (ja) | 2021-03-10 | 2024-03-05 | アムジエン・インコーポレーテツド | 組換えタンパク質の精製方法 |
WO2022191971A1 (en) | 2021-03-10 | 2022-09-15 | Amgen Inc. | Parallel chromatography systems and methods |
WO2022212831A1 (en) | 2021-04-02 | 2022-10-06 | Amgen Inc. | Mageb2 binding constructs |
AU2022255506A1 (en) | 2021-04-08 | 2023-11-09 | Marengo Therapeutics, Inc. | Multifunctional molecules binding to tcr and uses thereof |
CN117279947A (zh) | 2021-05-06 | 2023-12-22 | 安进研发(慕尼黑)股份有限公司 | 用于在增殖性疾病中使用的靶向cd20和cd22的抗原结合分子 |
EP4355778A1 (en) | 2021-06-17 | 2024-04-24 | Boehringer Ingelheim International GmbH | Novel tri-specific binding molecules |
CN113337514B (zh) * | 2021-08-05 | 2021-10-29 | 卡瑞济(北京)生命科技有限公司 | Tcr表达构建体以及其制备方法和用途 |
AU2022365116A1 (en) * | 2021-10-15 | 2024-05-02 | Amgen Inc. | Activatable polypeptide complex |
TW202326113A (zh) | 2021-10-27 | 2023-07-01 | 美商安進公司 | 使用光譜學進行的基於深度學習的預測 |
CA3237018A1 (en) | 2021-11-03 | 2023-05-11 | Joachim Koch | Bispecific cd16a binders |
AU2022382368A1 (en) | 2021-11-03 | 2024-05-02 | Affimed Gmbh | Bispecific cd16a binders |
WO2023164286A1 (en) | 2022-02-28 | 2023-08-31 | Xilio Development, Inc. | Engineered cd122 compositions and methods thereof |
US20230365641A1 (en) | 2022-02-28 | 2023-11-16 | Xilio Development, Inc. | Targeted cytokines and methods of use thereof |
TW202346368A (zh) | 2022-05-12 | 2023-12-01 | 德商安美基研究(慕尼黑)公司 | 具有增加的選擇性的多鏈多靶向性雙特異性抗原結合分子 |
US20240141007A1 (en) | 2022-07-15 | 2024-05-02 | Xilio Development, Inc. | Engineered cleavable carriers and methods of use thereof |
WO2024059675A2 (en) | 2022-09-14 | 2024-03-21 | Amgen Inc. | Bispecific molecule stabilizing composition |
WO2024077044A1 (en) | 2022-10-05 | 2024-04-11 | Amgen Inc. | Combination therapies comprising t-cell redirecting therapies and agonistic anti-il-2r antibodies or fragments thereof |
Family Cites Families (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU634186B2 (en) | 1988-11-11 | 1993-02-18 | Medical Research Council | Single domain ligands, receptors comprising said ligands, methods for their production, and use of said ligands and receptors |
US5637481A (en) * | 1993-02-01 | 1997-06-10 | Bristol-Myers Squibb Company | Expression vectors encoding bispecific fusion proteins and methods of producing biologically active bispecific fusion proteins in a mammalian cell |
US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
US20020062010A1 (en) | 1997-05-02 | 2002-05-23 | Genentech, Inc. | Method for making multispecific antibodies having heteromultimeric and common components |
JP4169478B2 (ja) * | 1998-04-21 | 2008-10-22 | マイクロメット アーゲー | Cd19×cd3特異的ポリペプチドおよびその使用 |
US6737056B1 (en) * | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
ES2649037T3 (es) | 2000-12-12 | 2018-01-09 | Medimmune, Llc | Moléculas con semividas prolongadas, composiciones y usos de las mismas |
CN1195779C (zh) * | 2001-05-24 | 2005-04-06 | 中国科学院遗传与发育生物学研究所 | 抗人卵巢癌抗人cd3双特异性抗体 |
MXPA05005160A (es) * | 2002-11-15 | 2005-07-22 | Genmab As | Anticuerpos monoclonales humanos contra la cd25. |
JP2008501621A (ja) * | 2003-05-31 | 2008-01-24 | マイクロメット アクツィエン ゲゼルシャフト | B細胞関連疾患を処置するための二重特異性抗cd3、抗cd19抗体構築物を含む薬学的組成物 |
US8367805B2 (en) | 2004-11-12 | 2013-02-05 | Xencor, Inc. | Fc variants with altered binding to FcRn |
AR056142A1 (es) | 2005-10-21 | 2007-09-19 | Amgen Inc | Metodos para generar el anticuerpo igg monovalente |
JP5082104B2 (ja) * | 2006-03-23 | 2012-11-28 | 国立大学法人東北大学 | 高機能性二重特異性抗体 |
CA2682626A1 (en) | 2007-04-03 | 2008-10-09 | Micromet Ag | Cross-species-specific bispecific binders |
JP2010524851A (ja) * | 2007-04-03 | 2010-07-22 | マイクロメット アーゲー | 種間特異的結合ドメイン |
KR101589759B1 (ko) * | 2007-04-03 | 2016-01-29 | 암젠 리서치 (뮌헨) 게엠베하 | 종간 특이적 cd3―입실론 결합 도메인 |
US20090155275A1 (en) * | 2007-07-31 | 2009-06-18 | Medimmune, Llc | Multispecific epitope binding proteins and uses thereof |
EP2050764A1 (en) * | 2007-10-15 | 2009-04-22 | sanofi-aventis | Novel polyvalent bispecific antibody format and uses thereof |
EP2570137A3 (en) * | 2007-11-07 | 2013-08-21 | Celldex Therapeutics, Inc. | Antibodies that bind human dendritic and epithelial cell 205 (DEC-205) |
SG10201605629VA (en) * | 2008-01-03 | 2016-08-30 | Scripps Research Inst | Antibody targeting through a modular recognition domain |
WO2009089004A1 (en) | 2008-01-07 | 2009-07-16 | Amgen Inc. | Method for making antibody fc-heterodimeric molecules using electrostatic steering effects |
AU2009256250B2 (en) | 2008-06-03 | 2013-05-30 | Abbvie Inc. | Dual variable domain immunoglobulins and uses thereof |
US9260522B2 (en) * | 2008-10-01 | 2016-02-16 | Amgen Research (Munich) Gmbh | Bispecific single chain antibodies with specificity for high molecular weight target antigens |
JP2013511281A (ja) * | 2009-11-23 | 2013-04-04 | アムジェン インコーポレイテッド | 単量体抗体Fc |
KR20120107122A (ko) * | 2009-12-22 | 2012-09-28 | 노파르티스 아게 | 치료법에서 사용하기 위한 4가 cd47―항체 불변 영역 융합 단백질 |
SG10201501342UA (en) * | 2010-02-24 | 2015-04-29 | Immunogen Inc | Folate receptor 1 antibodies and immunoconjugates and uses thereof |
ES2668895T3 (es) | 2011-03-16 | 2018-05-23 | Amgen Inc. | Variantes de Fc |
TWI743461B (zh) * | 2011-03-28 | 2021-10-21 | 法商賽諾菲公司 | 具有交叉結合區定向之雙重可變區類抗體結合蛋白 |
SG193514A1 (en) * | 2011-04-01 | 2013-10-30 | Immunogen Inc | Methods for increasing efficacy of folr1 cancer therapy |
AU2012245116A1 (en) * | 2011-04-20 | 2013-11-07 | Genmab A/S | Bispecific antibodies against HER2 and CD3 |
US20130078250A1 (en) * | 2011-08-23 | 2013-03-28 | Oliver Ast | Bispecific t cell activating antigen binding molecules |
AU2012323287B2 (en) * | 2011-10-10 | 2018-02-01 | Xencor, Inc. | A method for purifying antibodies |
JP2014533249A (ja) * | 2011-11-07 | 2014-12-11 | メディミューン,エルエルシー | 多重特異性を持つ多価結合タンパク質およびその使用 |
EP2794650B1 (en) | 2011-12-21 | 2019-08-14 | Amgen Inc. | Variant fc-polypeptides with enhanced binding to the neonatal fc receptor |
US20140302037A1 (en) | 2013-03-15 | 2014-10-09 | Amgen Inc. | BISPECIFIC-Fc MOLECULES |
-
2014
- 2014-03-13 US US14/210,178 patent/US20140302037A1/en not_active Abandoned
- 2014-03-14 MX MX2015012187A patent/MX2015012187A/es unknown
- 2014-03-14 MA MA38400A patent/MA38400A1/fr unknown
- 2014-03-14 BR BR112015023431A patent/BR112015023431A2/pt not_active Application Discontinuation
- 2014-03-14 CN CN201480027445.7A patent/CN105229031A/zh active Pending
- 2014-03-14 EA EA201591814A patent/EA201591814A1/ru unknown
- 2014-03-14 US US14/774,309 patent/US20160145340A1/en not_active Abandoned
- 2014-03-14 CA CA2902961A patent/CA2902961C/en active Active
- 2014-03-14 AU AU2014228829A patent/AU2014228829B2/en active Active
- 2014-03-14 WO PCT/US2014/029253 patent/WO2014144722A2/en active Application Filing
- 2014-03-14 PE PE2015002013A patent/PE20151998A1/es not_active Application Discontinuation
- 2014-03-14 JP JP2016503027A patent/JP6535654B2/ja active Active
- 2014-03-14 KR KR1020157028764A patent/KR20150139531A/ko not_active Application Discontinuation
- 2014-03-14 SG SG11201506647SA patent/SG11201506647SA/en unknown
- 2014-03-14 EP EP14717954.3A patent/EP2970477B1/en active Active
- 2014-03-14 AP AP2015008773A patent/AP2015008773A0/xx unknown
-
2015
- 2015-08-31 TN TN2015000379A patent/TN2015000379A1/en unknown
- 2015-09-09 IL IL241354A patent/IL241354A0/en unknown
- 2015-09-10 MX MX2021010416A patent/MX2021010416A/es unknown
- 2015-09-11 PH PH12015502083A patent/PH12015502083A1/en unknown
- 2015-09-15 CL CL2015002756A patent/CL2015002756A1/es unknown
- 2015-10-15 CR CR20150573A patent/CR20150573A/es unknown
-
2016
- 2016-02-25 HK HK16102153.1A patent/HK1214275A1/zh unknown
-
2018
- 2018-02-01 US US15/885,998 patent/US11753475B2/en active Active
- 2018-07-11 US US16/032,342 patent/US20190002568A1/en not_active Abandoned
-
2019
- 2019-03-28 JP JP2019062358A patent/JP6732988B2/ja active Active
-
2022
- 2022-03-17 US US17/697,632 patent/US20230212297A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CL2015002756A1 (es) | Moléculas fc biespecíficas | |
CU20190109A7 (es) | Moléculas de anticuerpo que se unen a cd73 | |
CY1123236T1 (el) | Αντισωματα διπλης εξειδικευσης που δεσμευονται με cd38 και cd3 | |
CL2017002752A1 (es) | Anticuerpos heterodiméricos que unen anticuerpos cd3 y tumorales | |
CL2017001361A1 (es) | Anticuerpos heterodiméricos que se unen a cd3 y cd38 | |
ECSP17040521A (es) | Anticuerpos heterodiméricos que se unen a CD3 y a antígenos tumorales | |
EA201790834A1 (ru) | Молекулы антител к pd-l1 и их применение | |
CU20160118A7 (es) | Moléculas de anticuerpo que se unen a tim-3 | |
CR20130359A (es) | Anticuerpos del cea | |
EA201791029A1 (ru) | Антитела против интерлейкина-33 и их применение | |
EA201591750A1 (ru) | Антитела против b7-h4 и иммуноконъюгаты | |
EA201791754A1 (ru) | АНТИТЕЛА, СОДЕРЖАЩИЕ ЗАВИСЯЩИЙ ОТ КОНЦЕНТРАЦИИ ИОНОВ АНТИГЕНСВЯЗЫВАЮЩИЙ ДОМЕН, ВАРИАНТЫ Fc-ОБЛАСТИ, IL-8-СВЯЗЫВАЮЩИЕ АНТИТЕЛА И ИХ ПРИМЕНЕНИЯ | |
MA43164A (fr) | Anticorps anti-il1rap, molécules bispécifiques de liaison à un antigène liant il1rap et cd3 et leurs utilisations | |
CR20150393A (es) | Moleculas biespecíficas de union a antígeno activadoras de células t | |
CR20150492A (es) | Proteínas de unión anti-lag-3 | |
EA201691321A1 (ru) | Антитела и способы их применения | |
ECSP14028523A (es) | Moléculas de anticuerpo anti-gcc y uso de las mismas | |
EA201590993A1 (ru) | Гетеродимерные иммуноглобулины | |
CO7151527A2 (es) | Anticuerpos anti-cd79 b e inmunoconjugados | |
BR112015018851A2 (pt) | anticorpos cd47 de não depleção de plaquetas e de não depleção de células vermelhas do sangue, e métodos de uso dos mesmos | |
BR112014019331A8 (pt) | anticorpos para cd47 e métodos de uso desses | |
EA201491947A1 (ru) | Антитела и иммуноконъюгаты к ly6e и способы применения | |
CR20150575A (es) | Anticuerpos humanos pac1 | |
EA201201016A1 (ru) | Антидоты антикоагулянтов | |
CR20130499A (es) | Anticuerpos monoclonales frente al inhibidor de la ruta del factor tisular (tfpi) |